Hypoxia‐inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications

What’s known on the subject? and What does the study add?

[1]  J. Carles,et al.  Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  M. Pearle,et al.  Novel stone-magnetizing microparticles: in vitro toxicity and biologic functionality analysis. , 2011, Journal of endourology.

[3]  W. Kassouf,et al.  Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer , 2009, Cancer biology & therapy.

[4]  B. Davies,et al.  Emerging targeted therapies for bladder cancer: a disease waiting for a drug , 2009, Cancer and Metastasis Reviews.

[5]  R. Motzer,et al.  Targeting renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Sonpavde,et al.  Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. , 2009, Urologic oncology.

[7]  S. Perkins,et al.  A multicenter phase II study of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC): Hoosier Oncology Group GU-0475. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Sabichi,et al.  Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells , 2009, Clinical Cancer Research.

[9]  W. Larchian,et al.  QUANTIFICATION OF SUNITINIB'S ANTITUMOR EFFECTS IN A LOCALIZED ORTHOTOPIC BLADDER CANCER MODEL , 2009 .

[10]  D. Schmidt,et al.  Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer. , 2009, Urology.

[11]  M. Milowsky,et al.  Advanced bladder cancer: Status of first‐line chemotherapy and the search for active agents in the second‐line setting , 2008, Cancer.

[12]  D. Danielpour,et al.  Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies , 2008, Molecular Cancer Therapeutics.

[13]  M. Milowsky,et al.  Final results of a phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC) , 2008 .

[14]  H. Nishiyama,et al.  Prognostic significance of HIF-1 alpha polymorphisms in transitional cell carcinoma of the bladder. , 2008, International journal of cancer.

[15]  H. Nishiyama,et al.  Prognostic significance of HIF‐1α polymorphisms in transitional cell carcinoma of the bladder , 2008 .

[16]  G. Kéri,et al.  Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. , 2008, The Journal of molecular diagnostics : JMD.

[17]  S. Horvath,et al.  Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma , 2008, PLoS medicine.

[18]  David C. Smith,et al.  Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. , 2007, Clinical genitourinary cancer.

[19]  P. Pandolfi,et al.  Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. , 2007, Cancer research.

[20]  R. Ozols,et al.  RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer Model , 2007, Clinical Cancer Research.

[21]  David C. Smith,et al.  Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  P. Russo,et al.  Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma. , 2007, The Journal of urology.

[23]  E. Duffield,et al.  The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers , 2007, Cancer Chemotherapy and Pharmacology.

[24]  E. Ioachim,et al.  Hypoxia-Inducible Factors HIF-1α and HIF-2α Expression in Bladder Cancer and Their Associations with Other Angiogenesis-Related Proteins , 2006, Urologia Internationalis.

[25]  D. Bajorin,et al.  Phase II study of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial carcinoma (UC): Analysis of the second cohort of CALGB 90102. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  G. Camenisch,et al.  Integration of Oxygen Signaling at the Consensus HRE , 2005, Science's STKE.

[27]  X. Wu,et al.  The phosphatidylinositol‐3 kinase pathway regulates bladder cancer cell invasion , 2004, BJU international.

[28]  I. Bodrogi,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Mazumdar,et al.  Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Groshen,et al.  Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. , 1995, Journal of the National Cancer Institute.

[31]  J. Richie,et al.  Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. , 1993, Journal of the National Cancer Institute.

[32]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[33]  R. Dhir.  Hypoxia-inducible factor-1α expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma , 2009 .

[34]  Peter A. Jones,et al.  Molecular targets and targeted therapies in bladder cancer management , 2008, World Journal of Urology.

[35]  W. Hung,et al.  Hypoxia-inducible factor-1alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma. , 2008, Journal of clinical pathology.

[36]  E. Ioachim,et al.  Hypoxia-inducible factors HIF-1alpha and HIF-2alpha expression in bladder cancer and their associations with other angiogenesis-related proteins. , 2006, Urologia internationalis.